RT, Brett AR, et al. Familial testicular cancer: a report of the UK family register, estimation of risk and a HLA class 1 sib-pair analysis. British Journal of Cancer. 1992;65(2): 255-262. 8. Boyle P, Zaridze DG. Risk factors for prostate and testicular cancer. European Journal of Cancer. 1993;29A: 1048-1055. 9. Testicular Cancer Overview. American Cancer Society. http://www.cancer.org/acs/groups/cid/documents/webcontent/003079-pdf.pdf [accesed: 2016-02-07]. 10. Braga IC, Cabral J, Louro N, et al. Testicular Cancer
Marta Piróg, Olga Padała, Marta Podgórniak, Maciej Putowski, Monika Sadowska and Wdowiak Artur
Kanok Preativatanyou and Sittisak Honsawek
Background: Recombinant human bone morphogenetic proteins (rhBMPs) have been characterized especially chondrogenic and osteogenic activity both in vitro and in vivo studies. However, delivery of more than one growth factor by sustained release carrier to orthopedic site has yet been questionable in terms of efficacy and synergism.
Objective: Evaluate osteoinductivity and synergistic effect of rhBMP-2 and -7 using absorbable collagen sponge (ACS) carrier system in vivo.
Methods: cDNA of BMP-2 and -7 active domains were cloned and expressed in Escherichia coli BL21 StarTM (DE3) using pRSETc expression system. Then, the purified rhBMPs were loaded onto ACS and evaluated by in vivo rat subcutaneous bioassay. Two and eight weeks postoperatively, all treated groups were histologically verified for evidence of new bone formation and neovascularization by hematoxylin-eosin staining and light microscopy.
Results: The Wistar rat treated with rhBMP-2 or -7/ACS exhibited new bone formation, compared to ACS control. The group treated with ACS supplemented with both rhBMP-2 and -7 significantly showed the osteoid matrix very well-organized into trabeculae-like structure with significant blood vessel invasion.
Conclusion: The osteogenic induction of rhBMPs was combined with ACS carrier in the in vivo bioassay. In addition, the combination of both two potent recombinant osteoinductive cytokines, rhBMP-2 and -7, with ACS carrier demonstrated synergistic effect and might be a more promising and effective choice for therapeutic applications.
Adawan Permpanich, Vithaya Kulsomboon and Kamol Udol
Despite several new treatments having been developed for the treatment of acute myocardial infarction (MI), the survivors from acute MI still have higher risk to subsequent cardiovascular (CV) events and mortality. Data from the Thai Acute Coronary Syndrome (ACS) Registry showed that approximately 20% of post-MI patients died, 4% had recurrent MI and 10% experienced non-fatal stroke within 1 year after their first MI. In the Asia-Pacific region, cardiovascular death accounts for nearly one third of all deaths, whereas ischemic heart disease and stroke comprise
Pyatat Tatsanavivat and Piyamitr Sritara
and inhospital outcomes of Thai Acute Coronary Syndrome Registry (TACSR): the difference from the Western world. J Med Assoc Thai. 2007; 90 (Suppl 1):1-11. 10. Saejueng B, Yipintsoi T, Chaisuksuwan R, Kehasukcharoen W, Boonsom W, Kanjanavanit R; Thai ACS-Registry group. Factors related to inhospital heart failure are very different for unstable angina and non-ST elevation myocardial infarction. Heart Vessels. 2009; 24:399-405. 11. ‘Leadership’. Wikipedia. 2011. Wikimedia Foundation, Inc. [cited Apr 18, 2011]. Available from http
Zeynep Tartan, Hakan Ekmekci, zlem Balci Ekmekci, Huriye Balci, Hulya Kasikcioglu, Nihat Ozer, Aleks Degirmencioglu, Emre Akkaya, Ender Ozal and Nese Cam
GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983; 51:606. 12. Oishi Y, Wakatsuki T, Nishikado A, Oki T, Ito S. Circulating adhesion molecules and severity of coronary atherosclerosis. Coron Artery Dis. 2000; 11: 77-81. 13. Qin QP, Wittfooth S, Pettersson K. Measurement and clinical significance of circulating PAPP-A in ACS patients. Clin Chim Acta. 2007; 380:59-67. 14. Lund J, Qin QP, Ilva T, Nikus K, Eskola M, Porela P, et al. Pregnancy-associated plasma
Shina Oranratanaphan and Nipon Khemapech
References 1. Classification and staging of malignant tumors in female pelvis (no authors listed). Acta Obstet Gynecol Scand. 1971; 50:1-7. 2. Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am J Clin Pathol. 2005; 123 (Suppl); s13-s57. 3. Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A. Conservative surgery for borderline ovarian tumors: a reviews. Gynecol Oncol. 2006; 100:185-91. Epub 2005 Oct 10. 4. Ozols RF, Rubin FC, Thomas GM. Epithelial ovarian
Palakorn Puttaruk, Duangnate Pipatsatitpong and Pilaiwan Siripurkpong
coronary syndrome (ACS). Level of sLOX-1 was a more specific and sensitive biomarker of ACS than others such as cardiac troponin T (cTnT), heart type-fatty acid binding protein, and high sensitive C-reactive protein [ 26 , 29 ]. The sLOX-1 was recommended as a suitable marker for early diagnosis of ACS than cTnT because 86% of the cTnT-negative patients showed sLOX-1 levels >1.0 ng/mL serum. Serum sLOX-1 levels were suggested to rise before ACS onset [ 25 ]. Taking together the previous results and the elevation of serum sLOX-1 levels associated with metabolic syndrome
Jiabei Li, Yanqi Zhang, Juan Wang, Dehui Qian, Hui Guo, Mingbao Song, Xiaojing Wu, Jun Jin, Junfu Huang and Lan Huang
[ 10 ]. However, only a couple of studies have drawn attention to the clinical importance of aspirin resistance in patients with acute coronary syndromes (ACS) [ 28 , 29 ], especially in those who were diagnosed as having UAP. In their CARS study, Eccleston et al. [ 28 ] demonstrated that aspirin resistance found by LTA could predict an increased risk of an in-hospital event in patients with ACS. UAP can contribute to a higher incidence of subsequent myocardial infarct and cardiovascular death because of the instability of arteriosclerosis plaques [ 12 ]. In our